Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Nov 19, 2024 10:55am
83 Views
Post# 36319761

RE:RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:RE:How does Accelerated Approval work note, i see his comment about accelerated approval, but given it takes pela around 4-6 months to actually demonstrate its benefit, that would seem to suggest it wouldn't be sooner that 2h 2025.

while it will take awhile to get the full 180+ patient enrollment, if pela can demonstrate outstanding results with some early readouts, suppose approval could be conditionally granted based on full results.  again, that would seem to suggest the latter part of next year.

that's not to say there couldn't be a buyout/partnership before then.

am i missing something here re: the timeline for accelerated approval?
<< Previous
Bullboard Posts
Next >>